Compare · BDX vs FNA
BDX vs FNA
Side-by-side comparison of Becton Dickinson and Company (BDX) and Paragon 28 Inc. (FNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and FNA operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $39.80B, about 36.5x FNA ($1.09B).
- BDX has hit the wire 12 times in the past 4 weeks while FNA has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 12 for FNA).
- Company
- Becton Dickinson and Company
- Paragon 28 Inc.
- Price
- $145.54+0.77%
- $13.10+0.15%
- Market cap
- $39.80B
- $1.09B
- 1M return
- -0.50%
- -
- 1Y return
- -14.72%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 12
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Paragon 28 Inc.
Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, such as gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback ankle fusion plating systems. The company also provides precision guide technology for various procedures consisting of MTP fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot; bunion or hallux valgus correction systems; phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics, such as bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Further, the company provides hammertoe implants, titanium wedges, and soft tissue fixators, as well as products for the various procedure, such as bunions, flatfoot, fracture fixation, and foot fracture. It serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was incorporated in 2010 and is headquartered in Englewood, Colorado.
Latest BDX
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional
Latest FNA
- Officer Dacosta Albert returned 11,753,724 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Wright Kristina returned 32,118 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Jarboe Matthew returned 575,320 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Oesterle Stephen N. returned 40,216 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Blackford Quentin S. returned 50,554 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Scanlon Meghan returned 42,113 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Officer Mccormack Robert S returned 203,134 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Officer Chahine Chadi returned 520,657 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Demski David M returned 74,307 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Johnson B Kristine returned 47,347 shares to the company, closing all direct ownership in the company (SEC Form 4)